Erin Burkhart - Mar 15, 2024 Form 4 Insider Report for BIOMARIN PHARMACEUTICAL INC (BMRN)

Role
GVP, Chief Accounting Officer
Signature
/s/ Tae Sang Yoo, Attorney-in-Fact
Stock symbol
BMRN
Transactions as of
Mar 15, 2024
Transactions value $
-$31,200
Form type
4
Date filed
3/19/2024, 08:55 PM
Previous filing
May 18, 2023
Next filing
Apr 12, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BMRN Common Stock Award $0 +4.72K +33.49% $0.00 18.8K Mar 15, 2024 Direct F1
transaction BMRN Common Stock Tax liability -$31.2K -372 -1.98% $83.87 18.4K Mar 18, 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BMRN Stock Option (Right to Buy Common Stock) Award $0 +7.05K $0.00 7.05K Mar 15, 2024 Common Stock 7.05K $83.87 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Restricted stock units granted March 15, 2024. Price not applicable.
F2 Option grant vests 12/48th on March 15, 2025 and 1/48th on the 15th day of each month thereafter.